Impact of COPD in patients with lung cancer and advanced disease treated with chemotherapy and/or tyrosine kinase inhibitors

International Journal of COPD

Volumn 9, Issue , 2014, Pages 1053-1058

  Izquierdo, José Luis ^a   Resano, Pilar ^a   Hachem, Abdulkader El ^a   Graziani, Desiré ^a   Almonacid, Carlos ^a   Sánchez, Ignacio M ^a  

^a HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

Author keywords

Chemotherapy; Chronic obstructive pulmonary disease; Extended disease; Lung cancer; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; SEX RATIO; SMALL CELL LUNG CANCER; SURVIVAL RATE; SURVIVAL TIME; ANTAGONISTS AND INHIBITORS; COMPLICATION; ENZYMOLOGY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84907807181     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S68766     Document Type: Article

References (31)

1. Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol. 2005;23(14):3175-3185.
2. Buist AS, McBurnie MA, Vollmer WM, et al; BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370(9589):741-750.
3. Loganathan RS, Stover DE, Shi W, Venkatraman E. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest. 2006;129(5):1305-1312.
4. Congleton J, Muers MF. The incidence of airflow obstruction in bronchial carcinoma, its relation to breathlessness, and response to bronchodilator therapy. Respir Med. 1995;89(4):291-296.
5. Løkke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax. 2006;61(11):935-939.
6. Sekine Y, Yamada Y, Chiyo M, et al. Association of chronic obstructive pulmonary disease and tumor recurrence in patients with stage IA lung cancer after complete resection. Ann Thorac Surg. 2007;84(3): 946-950.
7. Sekine Y, Kesler KA, Behnia M, Brooks-Brunn J, Sekine E, Brown JW. COPD may increase the incidence of refractory supraventricular arrhythmias following pulmonary resection for non-small cell lung cancer. Chest. 2001;120(6):1783-1790.
8. Algar FJ, Alvarez A, Salvatierra A, Baamonde C, Aranda JL, López-Pujol FJ. Predicting pulmonary complications after pneumonectomy for lung cancer. Eur J Cardiothorac Surg. 2003;23(2):201-208.
9. Sekine Y, Behnia M, Fujisawa T. Impact of COPD on pulmonary complications and on long-term survival of patients undergoing surgery for NSCLC. Lung Cancer. 2002;37(1):95-101.
10. Kondo R, Yoshida K, Eguchi T, et al. Clinical features of lung cancer in smokers with light and mild chronic obstructive pulmonary disease: a retrospective analysis of Japanese surgical cases. Eur J Cardiothorac Surg. 2011;40(6):1439-1443.
11. The Cooperative Group on Bronchogenic Carcinoma of SEPAR (GCCB-S). Sociedad Español de Neumología y Cirugía Torácica. [The surgery of bronchogenic carcinoma in Spain. A descriptive study]. Arch Bronconeumol. 1995;31(6):303-309. Spanish.
12. Gómez Sebastián G, Güell Rous R, González Valencia A, Fibla Alfara JJ, Estrada Saló G, León González C. [Impact of a rescue program on the operability of patients with bronchogenic carcinoma and chronic obstructive pulmonary disease]. Arch Bronconeumol. 2007;43(5):262-266. Spanish.
13. National Comprehensive Cancer Network [homepage on the Internet]. National Comprehensive Cancer Network. Fort Washington, PA: National Comprehensive Cancer Network; 2014. Available from: http://www.nccn.org. Accessed March 25, 2014.
14. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Impact of comorbidity on lung cancer survival. Int J Cancer. 2003;103(6):792-802.
15. Quanjer PH, editor. Standardized lung function testing. Report of Working Party Standardization of Lung Function Tests. European Community for Coal and Steel. Bull Eur Physiopathol Respir. 1983;19(Suppl 5):1-95.
16. Global Initiative for Chronic Obstructive Lung Disease [homepage on the Internet]. Global Initiative for Chronic Obstructive Lung Disease. Available from: http://www.goldcopd.com/. Accessed March 25, 2014.
17. Celli BR. Chronic obstructive pulmonary disease and lung cancer: common pathogenesis, shared clinical challenges. Proc Am Thorac Soc. 2012;9(2):74-79.
18. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-789.
19. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343(26):1902-1909.
20. Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J. 2009;34(2):380-386.
21. National Institute for Health and Care Excellence [webpage on the Internet]. Lung cancer: the diagnosis and treatment of lung cancer. London, UK: National Institute for Health and Care Excellence; 2011. Available from: http://Guidance.nice.org.uk/cg121. Accessed March 25, 2014.
22. López-Encuentra A, Astudillo J, Cerezal J, Gonzalez-Aragoneses F, Novoa N, Sánchez-Palencia A; Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pulmonary and Thoracic Surgery (GCCB-S). Prognostic value of chronic obstructive pulmonary disease in 2994 cases of lung cancer. Eur J Cardiothorac Surg. 2005;27(1): 8-13.
23. Battafarano RJ, Piccirillo JF, Meyers BF, et al. Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2002;123(2):280-287.
24. Kiri VA, Soriano J, Visick G, Fabbri L. Recent trends in lung cancer and its association with COPD: an analysis using the UK GP Research Database. Prim Care Respir J. 2010;19(1):57-61.
25. Rosenthal SA, Curran WJ, Herbert SH, et al. Clinical stage II non-small cell lung cancer treated with radiation therapy alone. The significance of clinically staged ipsilateral hilar adenopathy (N1 disease). Cancer. 1992;70(10):2410-2417.
26. Choe YH, Kim SR, Lee KS, et al. The use of PTC and RFA as treatment alternatives with low procedural morbidity in non-small cell lung cancer. Eur J Cancer. 2009;45(10):1773-1779.
27. McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005;63(4): 1010-1015.
28. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P; International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 2009;4(7):792-801.
29. Abal Arca J, Parente Lamelas I, Almazán Ortega R, Blanco Pérez J, Toubes Navarro ME, Marcos Velázquez P. [Lung cancer and COPD: a common combination]. Arch Bronconeumol. 2009;45(10):502-507. Spanish.
30. Papi A, Casoni G, Caramori G, et al. COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma. Thorax. 2004;59(8):679-681.
31. Nomura A, Stemmermann GN, Chyou PH, Marcus EB, Buist AS. Prospective study of pulmonary function and lung cancer. Am Rev Respir Dis. 1991;144(2):307-311.